Ginkgo Bioworks Holdings, Inc.
DNA
NYSE·Healthcare·Biotechnology·Mkt cap $454.0M
$6.95
▲ 0.00%
P/E
-1.39
Mkt Cap
$454.0M
52-Wk Range
$5.37–$17.58
52-Week Range
$5.37 - $17.58
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 37.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary cell programming platform with years of R&D investment and intellectual property
- Diversified end-market applications reducing dependency on single industry vertical
- Strategic partnerships with established companies like Selecta Biosciences expanding technology capabilities
- First-mover advantage in synthetic biology commercialization with experienced founding team
- Potential for significant cost reduction and sustainability benefits versus traditional chemical synthesis
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Moderate growth ahead
Increasing demand for sustainable and bio-based manufacturing alternatives across industries
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-14.1% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DNA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of -$0.75 vs -$0.90 consensus (+16.2% surprise). Revenue of $20.2M vs $24.1M expected (-16.2%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+16.2%
Revenue trend · last 8Q
—
+26%
+27%
-12%
-56%
-24%
-60%
-139%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$89.0M
$43.8M
$48.3M
$49.6M
$38.8M
$33.4M
$19.5M
-$19.5M
Margins · last 8Q
Gross
43.1%
Operating
—
Profit
—
Wall Street consensus
2 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
50%
Sell
50%
Median Price Target
—
Latest: BTIG · Sep 4, 2026
vs Industry
How DNA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related